Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSS39 injection in healthy Chinese subjects
NCT07057726Phase 1Enrolling by invitation
- Sponsor
- 3SBio
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Nanoparticles, Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SSS39 in autoimmune diseases (2 arms), sponsored by 3SBio. Primary endpoint: Safety and tolerance of SSS39 at Day 50. Started Oct 2024; status: enrolling by invitation.
02
Drugs
SSS39
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT07057726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07057726.